CHU Bordeaux
Bordeaux, 33000, France
NCT Number: NCT01266863
To rapidly adapt or deescalate the initially broad antibiotic treatment, an antibiogram analysis is required. E test strips have successfully provided an antibiogram 24 h after having been directly applied to bronchoalveolar lavage (BAL). An open-label, prospective cohort study of consecutive patients with hospital-acquired pneumonia will be conducted with the aim of validating a new method increasing the rapidity of antibiogram analysis compared to standard methods of culture. This antibiogram will be provided by E test strips directly applied to bronchoalveolar lavage (BAL) samples and analyzed from the 6th up to the 24th hour after its completion. The occurrence of major errors (S with E test method, I or R with standard method) and minor errors (I or R with E test method and S with standard method)will be observed and a comparison of H6, H10 and H24 results performed.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Bordeaux, 33000, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
E test strips directly applied to BAL
Time frame: 2 days
Time frame: 2 days
Université Victor Segalen Bordeaux 2
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04700202
Cross Infection, Disease Attributes
Dallas, Texas, United States
View Trial DetailsNCT04153682
Cross Infection, Disease Attributes
Créteil, France
View Trial DetailsNCT05483309
Cross Infection, Disease Attributes
Liverpool, United Kingdom
View Trial DetailsNCT04774094
Cross Infection, Disease Attributes
Fuyang, Anhui, China
View Trial Details